Catch up on the first three episodes of our Molecular Imaging in Focus series featuring interviews with Gary Ulaner, MD, PhD, Louise Emmett, MBChB, FRACP, FAANMS, MD, and Jeremie Calais, MD, PhD.
Molecular Imaging in Focus
Advertisement
In a recent interview, Jeremie Calais, MD, PhD, shared his perspective on recent research that compared the risk stratification capabilities of nomogram models incorporating PSMA PET data to established clinical risk scoring models from the European Association of Urology and the National Comprehensive Cancer Network (NCCN).
Advertisement
In a recent interview, Louise Emmett, MBChB, FRACP, FAANMS, MD, discussed recent findings from the Co-PSMA trial demonstrating enhanced detection of biochemical recurrence of prostate cancer with the PET agent 64Cu-SAR-bisPSMA.
In a recent interview, Gary Ulaner, M.D., Ph.D., discussed preliminary research with the newly patented 61Cu-NU101 radiodiagnostic agent and the potential with the agent’s half-life in expanding access to molecular imaging for prostate cancer detection.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What New Phase 3 MRI Findings Reveal About Survodutide in Patients with Obesity and MASLD
2
PSMA PET Plays Key Role in Multinational Phase 3 Trial of Perioperative Apalutamide for PCa
3
Molecular Imaging in Focus: SNMMI: Can a New Total Body PET Scanner Slash Scan Times and Bolster Sensitivity?
4
FDA Clears AI Software for Automated Contouring in Radiation Oncology
5